The discovery and development of our first-in-class Hec1/Nek2 inhibitor, oral anti-cancer drug T-1101 (Tosylate), have been accepted for an oral presentation at the 19th Annual
T-1301 Phase I clinical trial is to be initiated in Mid-December, 2021 in multiple centers in Taiwan. T-1301 is a small molecular multi-target tyrosine kinase
Following IND approval by the US FDA in Mid-June, 2021, Taivex submitted the Phase I clinical trial application to the Taiwan FDA later on June
T-1201 which IND application has been approved by US FDA and TFDA and the Phase I clinical trial has been initiated in June, 2021. T-1201
Taivex received US FDA Investigational New Drug Application (IND) Approval for T-1301 on June 17, 2021, to initiate phase I clinical trial for the treatment
Following IND approval by the US FDA in Mid-January, 2021, Taivex submitted the Phase I clinical trial application to the Taiwan FDA later on January
Taivex received US FDA Investigational New Drug Application (IND) Approval for T-1201 on December 15, 2020, to initiate phase I clinical trial for the treatment
T-1101 is a First-in-Class Hec1/Nek2 inhibitor that disrupts cancer cell cycle division thereby inhibits tumor growth in the body and receives TFDA approval to initiate
Taivex Therapeutics Corp. has identified a novel targeting small molecule anti-cancer drug, T-1101, which is new capsule form. T-1101 capsule IND application has been approved
Taivex received US FDA Investigational New Drug Application (IND) Approval for T-1101 capsule on Nov. 2021, to initiate phase I clinical trial. T-1101: T-1101 acts
